Abstract:7527 Background: Endostatin is one of the most effective inhibitors of tumor angiogenesis. Clinical studies have shown that chemotherapy combined with endostatin could improve response rate and the survival of patients. Methods: Chemotherapy-naive consenting patients with stage IIIB/IV NSCLC, performance status (PS) 0-2, aged 18-75 years and normal organ function, who had stable disease (SD) or above after receiving a first cycle TC, were enrolled in this study. Eligible patients were randomly assigned to the endostatin treatment group (TC + endostatin. T:175 mg/m2 d1, C:AUC = 5 d1, endostatin:7.5 mg/m2, d8-d21,q3w) or the control group (TC + placebo), and received three cycles of chemotherapy. The primary endpoint was time to progression (TTP); secondary endpoints were objective response rate (ORR), progression-free survival (PFS), clinical benefit rate (CBR), and safety. Results: From Jul 2007 to Aug 2008, 126 patients were randomized 1: 1 to the endostatin treatment group (Arm E) and the control group (Arm C).The ORR was 39.3% in Arm E and 23.0% in Arm C. The ORR of patients treated with endostatin plus chemotherapy increased 16.3% over those treated only with chemotherapy (p = 0.078). The CBR was 90.2% in Arm E and 67.2% in Arm C, and there was a significant difference between the two groups (p = 0.004). The median TTP in Arm E and Arm C were 7.1 and 6.3 months, respectively. The 24-week hazard ratio (HR) was 0.416 (95% confidence interval: 0.209-0.827, p = 0.012). The 16-week rates of PFS in Arm E and Arm C were 90% and 75%, respectively (p = 0.033). The 24- week rates of PFS in Arm E and Arm C were 78% and 59%, respectively (p = 0.017). Survival profile need further follow-up. There was no significant difference in the incidence rates of adverse events and serious adverse events between the two groups. Conclusions: In previously untreated advanced NSCLC, treatments with TC plus endostatin could significantly improve the 16-week and 24-week rates of PFS, ORR and CBR. The safety profile was similar. Chemotherapy combined with endostatin might play a role in the improvement of response rate and the survival of patients with advanced NSCLC. No significant financial relationships to disclose.

Study of Feasibility of Endostar Plus Gemcitabine and Cisplatin Regimen for Advanced Non-Small Cell Lung Cancer

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

CONTINUOUS ADMINISTRATION OF ENDOSTAR PLUS GP CHEMOTHERAPY IN LOCAL ADVANCED OR METASTATIC LUNG SQUAMOUS CELL CARCINOMA

Clinical trial of advanced non-small cell lung cancer by combination of gemci-tabine and cisplatin

Endostar Plus Gemcitabine/Cisplatin (gp) with Maintenance Endostar As First-Line Therapy for Advanced Non-Small Cell Lung Cancer (nsclc): Preliminary Results of A Phase Ii Study

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer

Influence of Different Drug Delivery Methods for Endostar Combined with a Gemcitabine/cisplatin Regimen in Locally Advanced or Metastatic Lung Squamous Cell Carcinoma

Phase II Study of Gemcitabine and Carboplatin in Patients with Advanced Non-Small-cell Lung Cancer.

Treatment of advanced non-small cell lung cancer with gemcitabine or docetaxel in combination with cisplatin:a systematic review

Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Vinorelbine in the Treatment of Advanced Non-Small Cell Lung Cancer (Nsclc).

Clinical observation on the efficacy of Endostar combined with platin-based chemotherapy for 55 cases of advanced non-small cell lung cancer

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Effects of Paclitaxel-Carboplatin (TC) Alone or with Endostatin for Advanced Non-Small Cell Lung Cancer (NSCLC).

[Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC)].

Clinical Study on Gemcitabine Combined with Nedaplatin or Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer

Combination of recombinant human endostatin and GP in the treatment of advanced non-small cell lung cancer

Efficacy of Gemcitabine Combined with Different Platinum Agents for Early Treatment of Advanced NSCLC

Gemcitabine Plus Cisplatin Combination in the Treatment of 16 Cases with Advanced Non Small Cell Lung Cancer

Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.

Real-world treatment pattern and comprehensive comparative effectiveness of Endostar plus different chemotherapy in advanced patients with non-small cell lung cancer

Comparasion on Two Combination Regimens of Nedaplatin Plus Gemcitabine and Cisplatin Plus Gemcitabine for Treatment of Patients with Advanced Non Small-cell Lung Cancer

Efficacy of Combined Gemcitabine and Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer